Most buyback programs run quietly through open-market purchases spread over months or years. An accelerated share repurchase, or ASR, is a different tool: the company pays a lump sum to a bank and receives a large block of shares almost immediately. Two 2026 announcements, from Boston Scientific and Cognizant, illustrate how the structure works and what companies disclose about it.
The basic mechanics
In a typical ASR, a company agrees to repurchase a fixed dollar amount of stock from an investment bank. The bank delivers an initial batch of shares to the company right away, often by borrowing them from existing holders. Over the following weeks or months, the bank buys shares in the open market to cover that borrowing. When the agreement ends, the final share count is settled based on the volume-weighted average price (VWAP) of the stock over the term, less a discount, and the company may receive additional shares or, depending on the contract, deliver shares or cash back.
The result is that a company can retire shares quickly, while the bank, not the company, takes on the work and the risk of buying them over time.
Case one: Boston Scientific, $2 billion
On May 18, 2026, Boston Scientific announced a $2 billion ASR with JPMorgan Chase Bank, part of a previously announced $5 billion repurchase authorization. According to the company’s release:
- The company would receive an initial delivery of shares worth 80% of the repurchase price, or $1.6 billion.
- That initial amount was based on a May 15 closing price of $52.68, equal to roughly 30.4 million shares.
- The final share count depends on the VWAP over the term, less a discount, and is subject to adjustments in the agreement.
- Final settlement was expected by June 30, 2026.
- About $3 billion would remain under the authorization after the ASR.
- The company expected a $0.02 net impact to full-year 2026 adjusted earnings per share, which it described as accretive to its April 22 guidance.
The arithmetic checks out: $1.6 billion divided by $52.68 is about 30.4 million shares. The $0.02 estimate also shows how modest the per-share effect can be even for a multi-billion-dollar transaction, particularly when the repurchase lands partway through the fiscal year.
Case two: Cognizant, $500 million
On May 21, 2026, Cognizant announced separate ASR agreements with Truist Bank and BNP Paribas totaling $500 million of its Class A common stock. The company said about 7.8 million shares would be delivered on May 21. As with Boston Scientific, the final number of shares depends on the VWAP less a discount, subject to potential adjustments. The release tied the transaction to an updated 2026 repurchase plan announced on May 18. The release did not state a completion date or a funding source in the portions reviewed.
Splitting a program between two banks, as Cognizant did, is a way of spreading execution across counterparties.
Why companies choose ASRs
| Feature | Open-market program | ASR |
|---|---|---|
| Share delivery | Gradual | Large initial block, balance at settlement |
| Cash timing | Spread over time | Paid up front |
| Price risk | Company bears it | Shifted to bank, adjusted at settlement |
| Flexibility | High; can pause | Contractually fixed |
The upfront share delivery reduces the weighted average share count sooner than gradual buying would, which can matter for reported earnings per share in the quarters that follow. Companies also sometimes use ASRs when they have a lump sum available, such as proceeds from an asset sale or new debt, or when they want to complete a repurchase before a certain date.
What investors can look for
ASR disclosures vary in completeness. Useful items include:
- The dollar amount and the share of the authorization it consumes.
- The initial delivery percentage, which was 80% in the Boston Scientific case.
- The expected completion date and final settlement terms.
- The estimated effect on earnings per share, when management provides one.
- Whether the cash outlay changes net debt or interest expense.
Limits and risks of the structure
An ASR is not inherently better or worse than an open-market program. Paying cash up front means the company commits capital at a single point in time, which removes the option to slow purchases if conditions change. The VWAP adjustment means the company’s average price is only known at settlement; if the shares rise during the term, fewer shares are ultimately delivered, and the reverse if they fall. The discount to VWAP offsets some of that, but the outcome depends on price behavior after the agreement.
Accounting treatment also matters. The upfront shares typically reduce the share count at once, while the remaining forward component is generally treated as an equity instrument. Company filings describe the specific treatment, and investors reading a quarterly report should compare the average diluted share count with the period-end share count to see the timing effect.
Finally, an ASR announcement says nothing by itself about whether a repurchase program is well timed or well funded. It is a method of executing a decision already made. As with any buyback, the more informative questions concern the price paid relative to value, the funding source, and the alternatives for the cash.
This article is informational, not investment advice.
Sources: Boston Scientific press release via BioSpace; Cognizant press release.